Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is a promising company with a unique technology platform for treating peanut allergies. Its Viaskin Peanut patch has shown promising results in clinical trials and could potentially change the landscape of peanut allergy treatment. Despite some potential financial and commercial risks, we believe DBVT is well-positioned to become a leader in the immunotherapy space with its differentiated approach and potential for future growth in other common allergens. We maintain a positive outlook and reiterate our Market Outperform rating and increased price target.

Bears say

DBV Technologies is facing multiple challenges and uncertainties, including the delay in FDA approval for Viaskin Peanut and the need for additional safety studies. This could impact the company's financial performance as it continues to invest in its pipeline and prepare for multiple BLA submissions. Furthermore, DBVT's reliance on a single product candidate and lack of diversification in its pipeline may make it a risky investment.

DBVT has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 4 analysts, DBVT has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.